Ventripoint Diagnostics
- Location : Toronto, ON
- Sector : Artificial Intelligence | Medical Technology
Growthbridge ventures is an Investor Relations and Marketing Outreach firm. The companies listed on this website and Portal are not an offer to the general public to purchase any form of securities. Every company listed on this website and Portal are listed for Investor Relations and marketing outreach, and should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the companies listed on this site, should they choose to engage in any form of investment. The information contained on these companies is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors and financial institutions and should not be used for any other reason or made available to any other person or entity without the prior written consent of Growthbridge ventures. The technology and process used on this website is protected by existing or pending patents owned by Growthbridge ventures. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Meet
Ventripoint Diagnostics Ltd. (TSXV: VPT; OTC: VPTDF) is a Toronto‑based medical technology company transforming cardiac ultrasound using artificial intelligence.
Its flagship platform, VMS+™ 4.0, converts standard 2D echocardiography images into precise 3D heart models and MRI‑comparable volumetric measurements, without requiring new imaging hardware. Using proprietary Knowledge Based Reconstruction (KBR) algorithms, VMS+ delivers accurate, reproducible cardiac metrics for all four chambers, even from low‑quality or “sparse” ultrasound data.
FDA‑cleared and approved in Canada, the EU, and the UK, VMS+ is already used by leading institutions including Mayo Clinic, Toronto SickKids, Seattle Children’s Hospital, Duke University Hospital, Erasmus (Rotterdam), Charité (Berlin), and Guy’s & St. Thomas (London). The technology was recognized with a Gold Edison Award for Precision Medicine.
Problem They’re Solving
Cardiovascular disease is the leading cause of death globally, yet MRI — the gold standard for cardiac volumetric measurement — is expensive, slow, and capacity‑constrained.
Many patients cannot undergo MRI due to implants, claustrophobia, or accessibility barriers.
Traditional cardiac ultrasound is fast and widely available but lacks accuracy, especially for the right ventricle, leading to misdiagnosis, repeat scans, and delayed treatment.
Ventripoint solves these challenges by enabling MRI‑equivalent accuracy using the ultrasound systems hospitals already own. VMS+ reduces rejected scans, improves reproducibility, and expands access to advanced cardiac imaging, including in remote, rural, and indigenous communities.
Where They Are Headed
Ventripoint is transitioning from technology development to commercial scale. The company is expanding VMS+ adoption from early clinical innovators to routine use in cardiology departments worldwide.
The next phase focuses on scaling the VMS+ Workstation, a software‑only solution that integrates directly into hospital workflows and 3D echo systems, enabling rapid deployment and licensing partnerships with major imaging manufacturers.
With regulatory approvals secured across key markets and growing clinical validation, Ventripoint is positioned to become the global standard for AI‑enhanced cardiac ultrasound.
Opportunity Highlights
- MRI‑Equivalent Accuracy Using Existing Ultrasound Equipment: Transforms standard 2D echo into precise 3D models and volumetric measurements with ±10% mean difference vs. MRI.
- Massive Installed Base & Global Market Demand: 40,000+ ultrasound systems in use today; >200 million cardiac patients who require routine imaging follow‑up.
- Regulatory‑Cleared & Clinically Validated: FDA 510(k), Health Canada, CE Mark (EU & UK). Used by top hospitals and supported by peer‑reviewed studies.
- Scalable AI Platform With Multiple Deployment Models: Console, workstation, and licensing pathways enable rapid adoption across hospitals, imaging networks, and OEM partners.
- Strong Clinical Momentum & Industry Recognition: Gold Edison Award for Precision Medicine; selected for NHS‑led AIRES cardio‑oncology study; expanding global partnerships.
Management Team
Hugh MacNaught — President & CEO
Life sciences executive with 30+ years of experience in developing, financing, and commercializing medical technologies across diagnostics, devices, and pharmaceuticals. Former roles include Amersham, Kodak, Boehringer Manheim (Roche), Philips, and Ventures West. Led Ventripoint through FDA clearance of VMS+ 4.0, Gold Edison Award recognition, and the launch of its subscription‑based Device‑as‑a‑Service model.
Dr. George Adams — Chair
Scientist, entrepreneur, and long‑standing leader at Ventripoint. Former CEO and now Executive Chairman. Founder of 30+ life science companies that have raised over $100M. Former CEO of Amorfix Life Sciences, Chairman of Sernova Corp., and President & CEO of University of Toronto Innovations Foundation. World Economic Forum Technology Pioneer.
David Swetlow — Chief Financial Officer
CPA with extensive public‑company finance experience across high‑growth medical technology firms. Former senior finance roles at Sernova, Ondine, Protox, QLT, and others. Specializes in capital markets strategy, commercialization scale‑up, and governance.
Matt Dobson — Marketing Director
Strategic marketing leader with experience at GSK, Coca‑Cola, and Philips. Skilled in product positioning, customer insights, and market development across global healthcare markets.
Philip Toleikis — Director
Former President & CEO of Sernova Corp. (2009–2023). Expert in medical device commercialization, regulatory strategy, and IP development. Secured over $100M in financings and built a global patent portfolio.
Key Metrics
- Founded: 2007
- Regulatory Approvals: FDA 510(k), Health Canada, CE Mark (EU & UK)
- Installed Base: 40,000+ ultrasound systems compatible
- Market Size: $10B+ global cardiac imaging market; $2B+ ultrasound segment
- Clinical Validation: ±10% mean difference vs. MRI; 95% confidence
- Key Customers: Mayo Clinic, Duke University, SickKids, Charité, Erasmus, Guy’s & St. Thomas
Milestones
- FDA 510(k) clearance for VMS+ 4.0
- CE Mark (EU & UK) and Health Canada approval
- Gold Edison Award for Precision Medicine (2026)
- Selected for NHS AIRES cardio‑oncology study (2026)
- Sales to Mayo Clinic and Duke University Hospital
- Launch of subscription Device‑as‑a‑Service model
- Global licensing discussions underway with major imaging OEMs
Send us your contact information and our market specialist will reach out you.
